[HTML][HTML] Canagliflozin, an Inhibitor of the Na+-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia
B Shim, JA Stokum, M Moyer, N Tsymbalyuk… - Cells, 2023 - mdpi.com
Brain swelling is a major cause of death and disability in ischemic stroke. Drugs of the
gliflozin class, which target the Na+-coupled D-glucose cotransporter, SGLT2, are approved …
gliflozin class, which target the Na+-coupled D-glucose cotransporter, SGLT2, are approved …
[HTML][HTML] Sodium-glucose cotransporter 2 inhibitors for the treatment of diabetic nephropathy: a review of clinical effectiveness
S Banerjee, A Grobelna - 2019 - europepmc.org
Diabetes mellitus or diabetes is a chronic condition and affects 8.2% or 382 million
individuals world-wide. According to data from 2013–2014, it was estimated that in Canada …
individuals world-wide. According to data from 2013–2014, it was estimated that in Canada …
[HTML][HTML] Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
AY Yang, HC Chen - International Journal of Clinical Pharmacy, 2021 - Springer
Background Previously, dapagliflozin was limited to patients with an estimated glomerular
filtration rate (eGFR)≥ 60 mL/min/1.73 m 2, while empagliflozin can be used for those with …
filtration rate (eGFR)≥ 60 mL/min/1.73 m 2, while empagliflozin can be used for those with …
Management of type 2 diabetes mellitus with overweight: Focus on SGLT-2 inhibitors and GLP-1 receptor agonists
SV Jargin - European Journal of Therapeutics, 2019 - eurjther.com
Abstract GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, along with the widely
used metformin, are the drug classes discussed in this mini-review. GLP-1RAs stimulate …
used metformin, are the drug classes discussed in this mini-review. GLP-1RAs stimulate …
Ertugliflozin in type 2 diabetes: a profile of its use
LJ Scott - Drugs & Therapy Perspectives, 2019 - Springer
Oral ertugliflozin (Steglatro™), a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor,
is approved in numerous countries as an adjunct to diet and exercise to improve glycaemic …
is approved in numerous countries as an adjunct to diet and exercise to improve glycaemic …
[PDF][PDF] 探討SGLT2 抑制劑對於第2 型糖尿病合併慢性腎疾病的影響與安全性
吳芳仁， 彭姿蓉， 左瑞美 - 內科學誌, 2019 - tsim.org.tw
探討SGLT2 抑制劑對於第2 型糖尿病合併慢性腎疾病的影響與安全性 Page 1 內科學誌2019:30:190-196
探討SGLT2 抑制劑對於第2 型糖尿病合併慢性腎疾病 的影響與安全性 吳芳仁彭姿蓉左瑞美 …
探討SGLT2 抑制劑對於第2 型糖尿病合併慢性腎疾病 的影響與安全性 吳芳仁彭姿蓉左瑞美 …
[PDF][PDF] Retrospective, observational, non-interventional analysis of non-glycemic parameters with SGLT2I on type 2 diabetes mellitus patients stable on OADs
S Roy - Indian J Appl Res, 2018 - researchgate.net
BACKGROUND: Sodium glucose co-transporter 2 inhibitors (SGLT2I) have been shown to
have extra-glycemic beneficial effects for type 2 diabetic patients. OBJECTIVE: The objective …
have extra-glycemic beneficial effects for type 2 diabetic patients. OBJECTIVE: The objective …
Renoprotective Mechanisms of SGLT2 Inhibitors in Type 2 Diabetes Patients with Chronic Kidney Disease
LHCC Pinto - Renoprotective Mechanisms of SGLT2 Inhibitors in …, 2022 - estudogeral.uc.pt
Background: Diabetes mellitus is a global epidemic estimated to affect more than 420 million
people worldwide and predicted to impact about 630 million until 2045. Chronic kidney …
people worldwide and predicted to impact about 630 million until 2045. Chronic kidney …